Medartis Holding (SWX:MED) Stock Can 18% EBITDA Margin Justify 78x P E

Medartis Holding stock has been on a tear, with a 3 month gain of about 22% heading into today, and the valuation now up at roughly 78x trailing P/E. The H1 2026 earnings print gave that optimism a fresh stress test. Revenue reached CHF 160.8m and the core EBITDA margin sat at 18%, which is the real headline. The market has been paying a rich multiple for growth and profitability, so this margin performance now becomes the key lens for both short term traders and long term holders.

Love Medartis Holding's margin profile but uneasy about paying roughly 78x trailing P/E for that growth story? Check out 283 resilient stocks with low risk scores to benchmark it against companies where valuation, balance sheet strength, and earnings quality are more closely aligned.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): CHF 160.835m vs. CHF 123.04m (up 30.7%)
• Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): CHF 5.123m profit vs. CHF 1.451m loss (swing to profit)
• Basic EPS (H1 2026 vs. H1 2025): CHF 0.4119 per share vs. CHF 0.117 loss per share (return to positive EPS)
• Core EBITDA Margin (H1 2026 vs. H1 2025): 18% vs. not disclosed for H1 2025 (margin in the high teens)

Tired of scrolling through walls of numbers and dense earnings tables? Get a clear visual picture of Medartis Holding, with its valuation front and center, in the company report for Medartis Holding.

Medartis earnings momentum backs specialized growth story

For investors leaning positive on Medartis, the latest half points in the right direction. Core revenue of CHF 160.8m with 17% organic growth and an 18% core EBITDA margin fits a picture of a focused medtech business gaining scale. Upper extremity now represents 71% of sales and is growing strongly, with TOUCH supporting both growth and profitability. Solid double digit expansion in the U.S. and EMEA, plus Medartis being cited among key players in foot and ankle devices, reinforces the idea that the specialized trauma and extremities franchise is being built out globally.

Execution, cash flow and integration risks still in view

The cautious view on Medartis also finds support. Free cash flow was about CHF 10m outflow in H1, even before management points to further heavy CapEx through 2026. Integration of Keri Medical and NeoOrtho, plus new manufacturing capacity in several regions, keeps execution risk elevated. Latin America distributor changes and gradual surgeon conversion for TOUCH show that adoption and channel shifts take time. FX headwinds and ongoing tariff exposure add further moving parts. The latest results suggest progress, but they do not remove the scale and integration questions that have worried some investors.

Scan Medartis Holding's debt load, cash demands and acquisition track record, then review our independent risk analysis for Medartis Holding which shows 2 important warning signs to spot any hidden structural warning signs.

Take Control Of Your Next Move

If Medartis Holding's strong H1 2026 margin profile and growth in upper extremity have caught your attention but the roughly 78x trailing P/E gives you pause, register for free with Simply Wall St and add it to your Watchlist to monitor the share price against fair value and wait for a setup that fits your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter to your holdings. For a longer term view, tap into crowd sentiment and different angles on Medartis Holding through the Community so you are never relying on a single opinion. By surfacing potential catalysts and risks early, Simply Wall St helps you act with confidence and stay a step ahead of the market.

Curious About Fresh Alternatives To Medartis

Some stocks are already building quiet breakout momentum while most investors are still looking the other way. Check a curated set of fresh ideas before the crowd and act now.

• Spot companies quietly building staying power with strong cash generation and steady balance sheets by scanning the curated list of solid balance sheet and fundamentals stocks (433 results) so you are not caught chasing late movers.
• Explore the early phase of potential AI momentum by reviewing hand picked 75 profitable AI stocks that aren't just burning cash that already back their story with real earnings instead of just hype.
• Consider possible shifts in global materials demand by assessing a focused group of 28 best rare earth metal stocks while they are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com